Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
46 hedge funds and large institutions have $34.5M invested in Biora Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 13 closing their positions.
97% more call options, than puts
Call options by funds: $2.52M | Put options by funds: $1.28M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 51 → 46 (-5)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
42% less capital invested
Capital invested by funds: $59.2M → $34.5M (-$24.7M)
69% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$364K |
| 3 |
Morgan Stanley
New York
|
+$64.7K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$40.5K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$646K |
| 2 |
VF
Virtu Financial
New York
|
-$431K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$346K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$239K |
| 5 |
Jane Street
New York
|
-$221K |
BIOR Hedge Fund Activity: Q2 2022 in Review
46 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q2 2022, worth a combined $34.5M — down 42% from $59.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BIOR and 8 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $460K. The largest seller was Millennium Management, cutting an estimated $646K.
- 46 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q2 2022, down from 51 in Q1 2022.
- Funds reported $34.5M of Biora Therapeutics, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
- 8 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q2 2022 and 13 closed out, a net change of -5 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q2 2022 was Vanguard Group, an estimated $460K added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q2 2022 was Millennium Management, an estimated $646K sold.
Based on aggregated 13F filings for Q2 2022.